Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD8630 versus placebo in adults with uncontrolled asthma at risk of exacerbations
NL-OMON59382Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2025
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing AZD8630 with Placebo (2 arms). Primary endpoint: Time to first CompEx Asthma event. Started Feb 2025; status: completed.
02
Drugs
azd8630
03
Conditions
asthma
Beyond the preview
Go deeper on NL-OMON59382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59382.